Step 1: Select the episodes & 1-minute challenges you'd like to consume
Step 2: Bank time as you blaze your way through the program
Step 3: Claim credit once available as shown in the Progress Bar
Step 4: Track the status of credits claimed in your profile
To experience MinuteCE for yourself, select one of the episodes below to start learning!
Providing Optimal Care for the Anticoagulated Patient with Intracranial Hemorrhage in the Acute Care Setting: Does the Patient Need Reversal, Repletion, or Surgery?
Providing Optimal Care for the Anticoagulated Patient with Intracranial Hemorrhage in the Acute Care Setting: Does the Patient Need Reversal, Repletion, or Surgery?
Emerging Data in the Management of Intracranial Hemorrhage in the Anticoagulated Patient
Emerging Data in the Management of Intracranial Hemorrhage in the Anticoagulated Patient
While Antiplatelets Are Good…They Aren’t for Everyone
While Antiplatelets Are Good…They Aren’t for Everyone
The Frontier of Stroke Diagnosis (RapidAI): How Can Artificial Intelligence Improve Acute Care for Ischemic and Hemorrhagic Stroke?
The Frontier of Stroke Diagnosis (RapidAI): How Can Artificial Intelligence Improve Acute Care for Ischemic and Hemorrhagic Stroke?
HER2 & PD-L1: Exploring Clinical Characteristics of G/GEJ Cancers in Relation to Biomarker Positivity
HER2 & PD-L1: Exploring Clinical Characteristics of G/GEJ Cancers in Relation to Biomarker Positivity
What Is the Current Standard for First-Line Treatment of Metastatic HER2-Positive G/GEJ Cancers?
What Is the Current Standard for First-Line Treatment of Metastatic HER2-Positive G/GEJ Cancers?
What Is the Current Standard for First-Line Treatment of Metastatic HER2-Negative G/GEJ Cancers?
What Is the Current Standard for First-Line Treatment of Metastatic HER2-Negative G/GEJ Cancers?
What Is the Evidence Supporting CLDN18.2 Targeting in Frontline Management of G/GEJ Cancers
What Is the Evidence Supporting CLDN18.2 Targeting in Frontline Management of G/GEJ Cancers
Incorporating Data Into Practice: Late-Breaking Highlights on G/GEJ Cancers From the 2024 GI Congress
Incorporating Data Into Practice: Late-Breaking Highlights on G/GEJ Cancers From the 2024 GI Congress
Claudin18.2: An Emerging Biomarker and Its Significance as a Therapeutic Target in G/GEJ Cancers
Claudin18.2: An Emerging Biomarker and Its Significance as a Therapeutic Target in G/GEJ Cancers
How Do You Counsel Patients About Amyloid-Related Imaging Abnormalities?
How Do You Counsel Patients About Amyloid-Related Imaging Abnormalities?
How Much Should We Worry About Amyloid-Related Imaging Abnormalities?
How Much Should We Worry About Amyloid-Related Imaging Abnormalities?
What is the Role of APOE4 Testing in Alzheimer’s Disease?
What is the Role of APOE4 Testing in Alzheimer’s Disease?